HIRMAb-IDUA regulatory update

FDA granted rare pediatric disease designation to AGT-181 from ArmaGen to treat mucopolysaccharidosis I (MPS I, Hurler syndrome). AGT-181 is in Phase I/IIa testing for MPS I. The product is alpha-L-i...